FTH — Faeth Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1829802 ·
Last close
$9.04
Market Cap
$233.63M
52W High
$42.14
52W Low
$7.45
ADV30
621,388
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -22,086,000 | -20,398,000 | 178,949,000 | 14,180,000 | 17,852,000 |
| Jun 2026 | 0 | — | -18,385,000 | -16,007,000 | 189,306,000 | 26,903,000 | 16,348,000 |
| Mar 2026 | 0 | — | -170,627,000 | -170,236,000 | 205,381,000 | 152,325,000 | 342,667,000 |
| Dec 2025 | 0 | — | -4,957,000 | -4,717,000 | 22,902,000 | 8,668,000 | 4,310,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-43,272,000
Investing CF
$-137,246,000
Financing CF
$184,136,000
CapEx
$-9,000
Dividends Paid
—
Buybacks
$-16,908,000
EPS Diluted TTM
$-138.70
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-489,778,000
Inventory
—
Receivables
—
ST Investments
$160,615,000
EBIT TTM
$-215,812,000
Pretax Income TTM
$-211,358,000
Interest Exp TTM
$32,000
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -22,288,000 | -21,085,000 | 22,902,000 | 4,310,000 | 18,592,000 | -20,453,000 |
| Dec 2024 | 0 | -31,663,000 | -30,157,000 | 45,361,000 | 6,975,000 | 38,386,000 | -24,670,000 |
| Dec 2023 | 0 | -37,064,000 | -34,101,000 | 74,374,000 | 9,479,000 | 64,895,000 | -32,023,000 |
| Dec 2022 | 0 | -50,188,000 | -48,588,000 | 118,375,000 | 14,968,000 | 103,407,000 | -39,026,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-195,528,000
OpCashFlow TTM
—
Assets (Latest)
$189,306,000
Forward EPS
$-3.67
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BIOA | BioAge Labs, Inc. | $234.35M | $5.10 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $235.60M | $2.11 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $230.39M | $3.81 | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $229.72M | $7.97 | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $242.22M | $6.39 | — |
News headlines (Yahoo Finance, 1h cache)
Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Can
2026-11-16 12:00 · Yahoo
Faeth Therapeutics to Participate in Upcoming November Investor Conferences
2026-11-11 12:30 · Yahoo
Faeth selloff ‘disproportionate’ to data, says Lucid Capital
2026-11-10 04:50 · Yahoo
Faeth Therapeutics Plummets 42%. What Investors Are Getting Wrong, According To Analysts.
2026-11-09 21:19 · Yahoo
Faeth Therapeutics Reports 33% Response Rate in Phase 2 PIKTOR Trial for Advanced Endometrial Cancer
2026-11-09 16:00 · Yahoo
Faeth Therapeutics reports positive Phase 2 results for endometrial cancer drug
2026-11-09 12:30 · Yahoo
Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
2026-11-06 21:00 · Yahoo
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-05 21:05 · Yahoo
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
2026-11-03 12:30 · Yahoo
Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout
2026-10-07 08:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.